Structure-Guided Drug Design Unlocks Broader Antiviral Coverage Against Deadly Paramyxoviruses
Scientists reveal how a measles antiviral also blocks Nipah virus and use structural insights to engineer more potent next-generation inhibitors.
Summary
Researchers discovered that ERDRP-0519, a drug originally developed against measles virus, also partially blocks Nipah virus — a deadly pathogen with pandemic potential. By mapping exactly how the drug binds to the viral copying machinery (RNA polymerase) in both viruses, the team identified why it works better against measles than Nipah. Nipah's polymerase must rearrange itself to accommodate the drug, weakening the interaction. Armed with this structural knowledge, scientists designed two improved compounds — GL22 and G671 — that make additional contacts with Nipah's polymerase and block viral replication more effectively. This work demonstrates how understanding molecular structure can rapidly accelerate the development of broad-spectrum antivirals against related but distinct dangerous viruses.
Detailed Summary
Emerging viral threats like Nipah virus (NiV) and measles remain serious global health concerns, yet antiviral treatment options are extremely limited. Developing drugs that work across multiple related viruses — so-called broad-spectrum antivirals — is a key pandemic preparedness strategy. This study advances that goal by revealing the structural basis for how one experimental antiviral compound interacts with polymerases from two distinct but related virus families.
The researchers investigated ERDRP-0519, a non-nucleoside inhibitor originally developed to block measles virus (MeV) replication. They found it also inhibits Nipah virus, a highly lethal Henipavirus, though with reduced potency. Using structural biology techniques, the team mapped the precise binding site of ERDRP-0519 within the RNA-dependent RNA polymerase (RdRp) of MeV, peste des petits ruminants virus (PPRV), and NiV.
The key finding was that ERDRP-0519 binds a conserved pocket in the RdRp palm domain across all three viruses, but forms more extensive molecular contacts with Morbillivirus polymerases. In NiV, the polymerase must undergo significant structural rearrangements to accommodate the drug, which costs energy and reduces binding affinity — explaining the weaker inhibition.
Armed with these structural insights, the team used rational drug design to create two derivatives, GL22 and G671, with extended chemical groups that forge additional contacts within NiV's polymerase. These new compounds showed enhanced biochemical inhibition of NiV replication by creating greater steric blockade of RNA and nucleotide binding.
This work is significant for pandemic preparedness, as Nipah virus carries a case fatality rate of up to 75% and has no approved treatments. The structure-guided approach demonstrated here provides a blueprint for rapidly optimizing existing antiviral scaffolds to cover emerging viral threats. Caveats include that the study is based on biochemical and structural data, and in vivo efficacy remains to be established.
Key Findings
- ERDRP-0519 cross-inhibits Nipah virus in addition to measles, revealing unexpected broad-spectrum antiviral potential.
- Nipah polymerase requires structural rearrangements to bind ERDRP-0519, explaining its reduced potency versus measles.
- New derivatives GL22 and G671 make additional polymerase contacts, boosting biochemical inhibition of Nipah virus.
- All three viruses share a conserved RdRp palm domain pocket — a promising target for broad-spectrum antiviral design.
- Structure-guided optimization can rapidly improve cross-virus inhibitor potency without starting from scratch.
Methodology
The study used structural biology to map ERDRP-0519 binding to RNA-dependent RNA polymerases from measles virus, PPRV, and Nipah virus, identifying key molecular interactions and conformational differences. Rational drug design was then applied to synthesize two optimized derivatives (GL22 and G671) with extended chemical moieties. Inhibitory potency was assessed through biochemical assays measuring RNA synthesis blockade.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, so methodological details and complete datasets could not be reviewed. The study appears to be primarily biochemical and structural; in vivo animal model or clinical efficacy data are not described in the abstract. The optimized compounds GL22 and G671 have not yet been evaluated for safety, pharmacokinetics, or antiviral activity in living systems.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.